Allergan Plc Acquisition by AbbVie Inc. – A Botox Deal with Some Wrinkles

Leading Independent Investment Research, Morningstar, Inc.

Morningstar

Leading Independent Investment Research

Morningstar, Inc.

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. We offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors. 

Morningstar provides data on more than 500,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 16 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries, with more than $180 billion in assets under advisement or management as of June 30, 2015. We have operations in 27 countries.

Download the Morningstar Fact Sheet : http://corporate.morningstar.com/US/documents/MarketingFactSheets/AboutMorningstarFactsheet.pdf

Equity Bottom-Up

<p class="p1"><strong>Innovative products, strong IP, and an unmatched aesthetics franchise drive Allergan's growth outlook.</strong></p><ul><li class="p1">We anticipate high-single-digit growth for Allergan through 2020 thanks to defensibility of the aesthetics business, strong intellectual property protection on most major products, and new innovative product launches, which includes pipeline opportunities to support Allergan's aesthetics, dry-eye, glaucoma, depression, and gastroenterology franchises.</li><li class="p1">Our forecasts for Allergan match consensus estimates, but we think the stock price doesn't reflect the above-average growth rate and profitability of this wide-moat firm.</li><li class="p1">Unlike lower quality specialty pharma peers, Allergan has low financial leverage, patent protection on key products well beyond 2020, and an innovative pipeline that supports future prescription growth and pricing power.</li><li class="p1">Additionally, Allergan possesses a disciplined management team and has not been overly reliant on price increases for growth, from our perspective.</li></ul>

Innovative products, strong IP, and an unmatched aesthetics franchise drive Allergan's growth outlook.We anticipate high-single-digit growth for Allergan through 2020 thanks to defensibility of the aesthetics business, strong intellectual property protection on most major products, and new innovative product launches, which includes pipeline opportunities to support Allergan's aesthetics, dry-eye, glaucoma, depression, and gastroenterology franchises.Our forecasts for Allergan match consensus estimates, but we think the stock price doesn't reflect the above-average growth rate and profitability of this wide-moat firm.Unlike lower quality specialty pharma peers, Allergan has low financial leverage, patent protection on key products well beyond 2020, and an innovative pipeline that supports future prescription growth and pricing power.Additionally, Allergan possesses a disciplined management team and has not been overly reliant on price increases for growth, from our perspective.

Allergan's Wide Moat Supports Industry-Leading Growth and Profit